Treatment News : Stanford’s Gene Therapy Helps Block HIV’s Ability to Bind to CD4s

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 25, 2013

Stanford’s Gene Therapy Helps Block HIV’s Ability to Bind to CD4s

In a step forward for genetic therapy research, scientists at Stanford University School of Medicine have created an advanced method of engineering CD4 cells to resist HIV infection, the San Francisco Chronicle reports. Ongoing research conducted by Sangamo BioSciences and the University of Pennsylvania has used gene therapy to effectively block the CCR5 receptor on the surface of CD4 cells to which HIV latches in order to ultimately gain entry into the cell. Building on that model, the Stanford study has gone further by creating another splice in the CCR5 receptor’s DNA and adding two additional genes—a method known as stacking. Consequently, the total of three synthetic genes helped prevent HIV’s entry into the cells through either the CCR5 or CXCR4 receptors. Their results were published in the journal Molecular Therapy.

The researchers tested their gene therapy in a laboratory setting (not in humans), inserting one, two or all three of the genes into CD4 cells before exposing them to the virus. Those cells that were exposed to either one or two gene modifications were somewhat protected against infection. But those that received the triple modification had more than a 1,200-fold protection against HIV molecules that use the CCR5 receptor for entry—called being “CCR5-tropic”—and a 1,700-fold protection against the CXCR4-tropic viruses.

In a statement, Matthew Porteus, MD, an associate professor of pediatrics at Stanford, said such tailored gene therapy could one day replace daily antiretrovirals as a treatment for HIV. However, actual human trials aren’t expected for another five years.

To read the Stanford statement, click here.

To read the San Francisco Chronicle story, click here.

Search: Stanford Medical School, HIV, CD4, CCR%, CXCR4, Molecular Therapy, University of Pennsylvania, San Francisco Chronicle, Sangamo BioSciences, Matthew Porteus, receptor.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (15 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dversescott
    Baltimore
    Maryland


    Newhopenate
    New Hope
    Pennsylvania


    sefarady
    New York
    California


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.